Lauri Strauss Leukemia Foundation
Endowed Fellows
At Memorial Sloan-Kettering Cancer Center, New York, NY
|
| The Lauri Strauss Leukemia Research fully endowed Fellowship at Memorial Sloan-Kettering Cancer Center, designed for a clinical investigator in leukemia and allied cancers, offers academically oriented physician training in medicine with clinical investigation and basic science research. |
| |
| This endowment provides funding for training in comprehensive care of the patient. Established in 1997 twelve Fellows have been working on fifteen individual Projects. |
| |
|
Jae Park, MD
2010 - 2011 - Optimizing Adoptive Therapy with CD19 Targeted T Cells in Patients with
B Cell Leukemias and Lymphomas.
Prabodhika Mallikaratchy, PhD
2009 - 2010 - Developing a new drug for chronic leukemia.
Tod Rosenblat, MD
2007- 2009 – Studying novel clinical trials of AML with antibody based radiotherapy.
Lei Zhu, PhD
2006 - 2007 – Development of y-Secretase inhibitors as novel anti-leukemia therapeutics.
Debjit Chattopadhyay, PhD
2005 - 2006 – Developing new methods to deliver drugs selectively to leukemia cells using novel nanomaterials.
Deborah Mulford, MD
2003 - 2005 - Review of treatments for AML.
John M. Burke, MD
2001 - 2003 - In clinical trials radio labeled antibodies will be used to treat patients with certain types of acute and chronic leukemias.
Timothy Aliff, MD
2000 - 2001 – The study of new combination chemotherapy approaches for acute lymphocytic leukemia. |
Steven Novick, MD, PhD
2000 - 2001 – Investigating novel treatment strategies for chronic leukemia.
Renier Brentjens, MD
1999 - 2000 – . The plan is to genetically engineer human T cells so that they will recognize and destroy human leukemia cells. The project is on the cutting-edge of genetics and immunotherapy research.
Robert Sokolic, MD
1999 - 2000 – The primary goal of this research is to investigate the proteins that are involved in the regulation of cell death in leukemia cells.
Steven Kossman, MD
1998 - 1999 – Development of a comprehensive treatment program for chronic leukemias focused on curative strategies that employ the combination of chemotherapy and immunologic techniques.
Elsje Barensdwaard, MD
1997 - 1998 – Preliminary experiments with the anti CD-19 antibody SJ25C1, when radiolabeled with Yttrium-90, show in vitro killing of B-cell lymphomas, compared with radiolabeled control antibody treatment. |
|
| |
| The Lauri Strauss Leukemia Research Fellowship Endowment provides an excellent opportunity
to have a significant impact upon the training of future leaders in leukemia and allied cancer research and
treatment, thus providing essential support for Memorial Sloan-Kettering Cancer Center
in its effort to achieve the progressive control and cure of the disease. |
| |
|
Email Us For More Information
|
